Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates
Summit Therapeutics climbed by 15.44 percent on Wednesday to close at $17.94 apiece, as investors repositioned portfolios ahead of updates on a clinical trial for its lung cancer treatment candidate, ...









